Zobrazeno 1 - 10
of 150
pro vyhledávání: '"Michael L, Wang"'
Autor:
Wojciech Jurczak, Pier Luigi Zinzani, Toby A. Eyre, Chan Y. Cheah, Chaitra S. Ujjani, Koji Izutsu, Shuo MA, Ian Flinn, Alvaro J. Alencar, David Lewis, Krish Patel, Kami Maddocks, Yucai Wang, Talha Munir, Andrew D. Zelenetz, Minna Balbas, Donald E. Tsai, Chunxiao Wang, Michael L. Wang, Nirav N. Shah
Publikováno v:
HemaSphere, Vol 7, p e45636b5 (2023)
Externí odkaz:
https://doaj.org/article/a4b327c6fbcf4927add163f9f9b4f90e
Autor:
Yucai Wang, Shouhao Zhou, Xinyue Qi, Fang Yang, Matthew J. Maurer, Thomas M. Habermann, Thomas E. Witzig, Michael L. Wang, Grzegorz S. Nowakowski
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract Front-line treatment for follicular lymphoma has evolved with the introduction of maintenance therapy, bendamustine (Benda), obinutuzumab (G), and lenalidomide (Len). We conducted a random-effects Bayesian network meta-analysis (NMA) of phas
Externí odkaz:
https://doaj.org/article/51f844b659894e18bc8376532b1a56f9
Publikováno v:
Journal of the National Cancer Center, Vol 1, Iss 3, Pp 88-96 (2021)
B cell malignancies pose challenges due to therapeutic resistance and repeated relapse. Advances in adoptive cellular therapies including chimeric antigen receptor (CAR)-T cells have the potential to transform the treatment landscape in hematological
Externí odkaz:
https://doaj.org/article/13baf7e057a4433f9f07fc68916d37eb
Autor:
Martin Dreyling, Andre Goy, Georg Hess, Brad S. Kahl, José-Ángel Hernández-Rivas, Natasha Schuier, Keqin Qi, Sanjay Deshpande, Angeline Zhu, Lori Parisi, Michael L. Wang
Publikováno v:
HemaSphere, Vol 6, Iss 5, p e712 (2022)
Externí odkaz:
https://doaj.org/article/89d6d5174cfe41b2b75b096c51736769
Autor:
Wen-Hao Guo, Xiaoli Qi, Xin Yu, Yang Liu, Chan-I Chung, Fang Bai, Xingcheng Lin, Dong Lu, Lingfei Wang, Jianwei Chen, Lynn Hsiao Su, Krystle J. Nomie, Feng Li, Meng C. Wang, Xiaokun Shu, José N. Onuchic, Jennifer A. Woyach, Michael L. Wang, Jin Wang
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-16 (2020)
PROTACs have emerged as promising therapeutic agents but their cellular uptake is often inefficient. Here, the authors show that reversible covalent warhead chemistry improves PROTAC intracellular accumulation and target engagement, and develop a dua
Externí odkaz:
https://doaj.org/article/4979b2c9fe654e15a019e2b5da2998c8
Autor:
Serageldin Kamel, Lucia Martiniova, Eslam Aboismail, Joo Schmidt, Sairah Ahmed, Ranjit Nair, Raphael E. Steiner, Michael L. Wang, Sarita Soebianto, Gregory Ravizzini, Tinsu Pan, Hun Ju Lee
Publikováno v:
HemaSphere, Vol 6, Pp 48-48 (2022)
Externí odkaz:
https://doaj.org/article/070e805b624c45f8b9d902d722549360
Autor:
Yucai Wang, Preetesh Jain, Frederick L. Locke, Matthew J. Maurer, Matthew J. Frank, Javier L. Munoz, Saurabh Dahiya, Amer M. Beitinjaneh, Miriam T. Jacobs, Joseph P. Mcguirk, Julie M. Vose, Andre Goy, Charalambos Andreadis, Brian T. Hill, Kathleen A. Dorritie, Olalekan O. Oluwole, Abhinav Deol, Jonas Paludo, Bijal Shah, Trent Wang, Rahul Banerjee, David B. Miklos, Aaron P. Rapoport, Lazaros Lekakis, Armin Ghobadi, Sattva S. Neelapu, Yi Lin, Michael L. Wang, Michael D. Jain
Publikováno v:
Journal of Clinical Oncology. 41:2594-2606
PURPOSE Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory mantle cell lymphoma (MCL). This therapy was approved on the basis of the single-arm phase II
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1ebedb9cdef4e30b7e8b0e20978feb3
https://doi.org/10.1200/jco.22.01797
https://doi.org/10.1200/jco.22.01797
Autor:
Wern Lynn Ng, Yucai Wang, Allison M. Bock, Dragan Jevremovic, Michael L. Wang, Grzegorz S. Nowakowski
Publikováno v:
Leukemia & Lymphoma. :1-5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::074df9ceb3be081ba9bb0bbd7c2a6077
https://doi.org/10.1080/10428194.2023.2196592
https://doi.org/10.1080/10428194.2023.2196592
Autor:
Jimmy Lee, Liang Leo Zhang, Wenjun Wu, Hui Guo, Yan Li, Madina Sukhanova, Girish Venkataraman, Hui Zhang, Mir Alikhan, Pin Lu, Ailin Guo, Natalie Galanina, Jorge Andrade, Michael L. Wang, Y. Lynn Wang
Publikováno v:
Blood Advances, Vol 2, Iss 16, Pp 2039-2051 (2018)
Abstract: The BTK inhibitor ibrutinib has demonstrated a remarkable therapeutic effect in mantle cell lymphoma (MCL). However, approximately one-third of patients do not respond to the drug initially. To identify the mechanisms underlying primary ibr
Externí odkaz:
https://doaj.org/article/a15f163217104838a6c52f480e8b1a38
Autor:
Haige Ye, Aakash Desai, Shengjian Huang, Dayoung Jung, Richard Champlin, Dongfeng Zeng, Fangfang Yan, Krystle Nomie, Jorge Romaguera, Makhdum Ahmed, Michael L. Wang
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 37, Iss 1, Pp 1-12 (2018)
Abstract The natural history of mantle cell lymphoma (MCL) is a continuous process with the vicious cycle of remission and recurrence. Because MCL cells are most vulnerable before their exposure to therapeutic agents, front-line therapy could elimina
Externí odkaz:
https://doaj.org/article/0c516736ebdf409d8b21c9565be463d2